Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Transarterial chemoembolization in a patient with severe reactions to iodinated contrast: Successful treatment using gadolinium contrast with C-arm computed tomography.

Pugh R, Wessel B, Barve A, Vyleta MS.

Radiol Case Rep. 2018 Dec 4;14(3):299-303. doi: 10.1016/j.radcr.2018.11.011. eCollection 2019 Mar.

2.

A first-in-human, randomized, double-blind, placebo-controlled, single and multiple ascending oral dose study to assess the safety, tolerability, and pharmacokinetics of BZF961 with and without ritonavir in healthy adult volunteers.

Youngberg S, Brandt E, Barve A, Machineni S, Jones CT, Dabovic K, Jones CL, Colvin RA.

J Drug Assess. 2018 Oct 24;7(1):66-74. doi: 10.1080/21556660.2018.1535438. eCollection 2018.

3.

The Safety and Antiviral Activity of BZF961 with or without Ritonavir in Patients Infected with Hepatitis C Virus: A Randomized, Multicenter Trial.

Lawitz E, Bidair M, Marbury T, Jones CT, Barve A, Magnusson B, Barkan DT, Bodendorf U, Bracken K, Canino E, Chen D, Dabovic K, Heimbach T, Ison M, Jones CL, Kovacs SJ, Lakshman JP, Li B, Raman P, Steiner-Swiat R, Thohan S, Wong KA, Zhong W, Colvin RA.

Clin Ther. 2018 Sep;40(9):1567-1581.e4. doi: 10.1016/j.clinthera.2018.07.019. Epub 2018 Sep 2.

PMID:
30185394
4.

Comparative utility of NRG and NRGS mice for the study of normal hematopoiesis, leukemogenesis, and therapeutic response.

Barve A, Casson L, Krem M, Wunderlich M, Mulloy JC, Beverly LJ.

Exp Hematol. 2018 Nov;67:18-31. doi: 10.1016/j.exphem.2018.08.004. Epub 2018 Aug 17.

PMID:
30125602
5.

Efficacy and safety of MYL-1501D versus insulin glargine in patients with type 2 diabetes after 24 weeks: Results of the phase III INSTRIDE 2 study.

Blevins TC, Barve A, Sun B, Raiter Y, Aubonnet P, Muniz R, Athalye S, Ankersen M.

Diabetes Obes Metab. 2019 Jan;21(1):129-135. doi: 10.1111/dom.13495. Epub 2018 Sep 4.

PMID:
30112792
6.

A pharmacokinetics phase 1 bioequivalence study of the trastuzumab biosimilar MYL-1401O vs. EU-trastuzumab and US-trastuzumab.

Waller CF, Vutikullird A, Lawrence TE, Shaw A, Liu MS, Baczkowski M, Sharma R, Barve A, Goyal P, Donnelly C, Sengupta N, Pennella EJ.

Br J Clin Pharmacol. 2018 Oct;84(10):2336-2343. doi: 10.1111/bcp.13689. Epub 2018 Jul 31.

PMID:
29926514
7.

Prurigo-like herpes simplex.

Barve A.

Int J Dermatol. 2018 Aug;57(8):e55-e57. doi: 10.1111/ijd.14063. Epub 2018 May 27. No abstract available.

PMID:
29806078
8.

The Antiarrhythmic Drug, Amiodarone, Decreases AKT Activity and Sensitizes Human Acute Myeloid Leukemia Cells to Apoptosis by ABT-263.

Ketchem CJ, Kucera C, Barve A, Beverly LJ.

Am J Med Sci. 2018 May;355(5):488-496. doi: 10.1016/j.amjms.2018.01.011. Epub 2018 Feb 6.

9.

A pharmacokinetics and pharmacodynamics equivalence trial of the proposed pegfilgrastim biosimilar, MYL-1401H, versus reference pegfilgrastim.

Waller CF, Tiessen RG, Lawrence TE, Shaw A, Liu MS, Sharma R, Baczkowski M, Kothekar MA, Micales CE, Barve A, Ranganna GM, Pennella EJ.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1087-1095. doi: 10.1007/s00432-018-2643-3. Epub 2018 Apr 18.

PMID:
29671069
10.

Efficacy and safety of MYL-1501D vs insulin glargine in patients with type 1 diabetes after 52 weeks: Results of the INSTRIDE 1 phase III study.

Blevins TC, Barve A, Sun B, Ankersen M.

Diabetes Obes Metab. 2018 Aug;20(8):1944-1950. doi: 10.1111/dom.13322. Epub 2018 May 7.

PMID:
29656504
11.

Silencing of α-complex protein-2 reverses alcohol- and cytokine-induced fibrogenesis in hepatic stellate cells.

Liu H, Chen Z, Jin W, Barve A, Wan YY, Cheng K.

Liver Res. 2017 Jun;1(1):70-79. doi: 10.1016/j.livres.2017.05.003.

12.

Comparison of Avidin, Neutravidin, and Streptavidin as Nanocarriers for Efficient siRNA Delivery.

Jain A, Barve A, Zhao Z, Jin W, Cheng K.

Mol Pharm. 2017 May 1;14(5):1517-1527. doi: 10.1021/acs.molpharmaceut.6b00933. Epub 2017 Jan 13.

PMID:
28026957
13.

Effect of a Proposed Trastuzumab Biosimilar Compared With Trastuzumab on Overall Response Rate in Patients With ERBB2 (HER2)-Positive Metastatic Breast Cancer: A Randomized Clinical Trial.

Rugo HS, Barve A, Waller CF, Hernandez-Bronchud M, Herson J, Yuan J, Sharma R, Baczkowski M, Kothekar M, Loganathan S, Manikhas A, Bondarenko I, Mukhametshina G, Nemsadze G, Parra JD, Abesamis-Tiambeng ML, Baramidze K, Akewanlop C, Vynnychenko I, Sriuranpong V, Mamillapalli G, Ray S, Yanez Ruiz EP, Pennella E; Heritage Study Investigators.

JAMA. 2017 Jan 3;317(1):37-47. doi: 10.1001/jama.2016.18305.

PMID:
27918780
14.

Discovery of PSMA-specific peptide ligands for targeted drug delivery.

Jin W, Qin B, Chen Z, Liu H, Barve A, Cheng K.

Int J Pharm. 2016 Nov 20;513(1-2):138-147. doi: 10.1016/j.ijpharm.2016.08.048. Epub 2016 Aug 28.

PMID:
27582001
15.

An enzyme-responsive conjugate improves the delivery of a PI3K inhibitor to prostate cancer.

Barve A, Jain A, Liu H, Jin W, Cheng K.

Nanomedicine. 2016 Nov;12(8):2373-2381. doi: 10.1016/j.nano.2016.07.007. Epub 2016 Jul 29.

16.

UV induced foot duplication in regenerating hydra is mediated by metalloproteinases and modulation of the Wnt pathway.

Krishnapati LS, Londhe R, Deoli V, Barve A, Ghaskadbi S, Ghaskadbi S.

Int J Dev Biol. 2016;60(4-6):111-7. doi: 10.1387/ijdb.130253sg.

17.

Clinical Exposure Boost Predictions by Integrating Cytochrome P450 3A4-Humanized Mouse Studies With PBPK Modeling.

Zhang J, Heimbach T, Scheer N, Barve A, Li W, Lin W, He H.

J Pharm Sci. 2016 Apr;105(4):1398-404. doi: 10.1016/j.xphs.2016.01.021.

PMID:
27019957
18.

Simeprevir and sofosbuvir with or without ribavirin to treat recurrent genotype 1 hepatitis C virus infection after orthotopic liver transplantation.

Crittenden NE, Buchanan LA, Pinkston CM, Cave B, Barve A, Marsano L, McClain CJ, Jones CM, Marvin MR, Davis EG, Kuns-Adkins CB, Gedaly R, Brock G, Shah MB, Rosenau J, Cave MC.

Liver Transpl. 2016 May;22(5):635-43. doi: 10.1002/lt.24422.

19.

Fluorescein Tri-Aldehyde Promotes the Selective Detection of Homocysteine.

Barve A, Lowry M, Escobedo JO, Thainashmuthu J, Strongin RM.

J Fluoresc. 2016 Mar;26(2):731-7. doi: 10.1007/s10895-015-1762-3. Epub 2016 Jan 16.

20.

Exhaustive Analysis of a Genotype Space Comprising 10(15 )Central Carbon Metabolisms Reveals an Organization Conducive to Metabolic Innovation.

Hosseini SR, Barve A, Wagner A.

PLoS Comput Biol. 2015 Aug 7;11(8):e1004329. doi: 10.1371/journal.pcbi.1004329. eCollection 2015 Aug.

21.

Long-term efficacy and safety of itolizumab in patients with moderate-to-severe chronic plaque psoriasis: A double-blind, randomized-withdrawal, placebo-controlled study.

Dogra S, D S K, Budamakuntla L, Srinivas CR, Khopkar U, Gupta S, Shetty N, Pratap DV, Gopal MG, Rao TN, Garg V, Sumathy TK, Saraswat A, Bhat R, Kura M, Pandey N, Shah R, Sai Krishna K, Padmaja D, Manmohan G, M S R, Barve A, Montero E.

J Am Acad Dermatol. 2015 Aug;73(2):331-3.e1. doi: 10.1016/j.jaad.2015.03.040. No abstract available.

PMID:
26183983
22.

Homodyne detection of coherence and phase shift of a quantum dot in a cavity.

Bakker MP, Snijders H, Löffler W, Barve AV, Coldren LA, Bouwmeester D, van Exter MP.

Opt Lett. 2015 Jul 1;40(13):3173-6. doi: 10.1364/OL.40.003173.

PMID:
26125395
23.

Itolizumab in combination with methotrexate modulates active rheumatoid arthritis: safety and efficacy from a phase 2, randomized, open-label, parallel-group, dose-ranging study.

Chopra A, Chandrashekara S, Iyer R, Rajasekhar L, Shetty N, Veeravalli SM, Ghosh A, Merchant M, Oak J, Londhey V, Barve A, Ramakrishnan MS, Montero E.

Clin Rheumatol. 2016 Apr;35(4):1059-64. doi: 10.1007/s10067-015-2988-9. Epub 2015 Jun 7.

PMID:
26050104
24.

The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.

Barve A, Kovacs SJ, Ke J, Crabbe R, Grosgurin P, Menetrey A, Nicolas-Métral V, Dabovic K, Dole K, Zhang J, Praestgaard J, Sunkara G, Stein D.

Clin Pharmacol Drug Dev. 2015 Jan;4(1):25-32. doi: 10.1002/cpdd.114. Epub 2014 May 26.

PMID:
27128001
25.

Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir.

Xia B, Barve A, Heimbach T, Zhang T, Gu H, Wang L, Einolf H, Alexander N, Hanna I, Ke J, Mangold JB, He H, Sunkara G.

Eur J Pharm Sci. 2014 Oct 15;63:103-12. doi: 10.1016/j.ejps.2014.06.021. Epub 2014 Jul 4.

PMID:
25008118
26.

Differences in heterocycle basicity distinguish homocysteine from cysteine using aldehyde-bearing fluorophores.

Barve A, Lowry M, Escobedo JO, Huynh KT, Hakuna L, Strongin RM.

Chem Commun (Camb). 2014 Aug 4;50(60):8219-22. doi: 10.1039/c4cc03527e.

27.

Prostate cancer relevant antigens and enzymes for targeted drug delivery.

Barve A, Jin W, Cheng K.

J Control Release. 2014 Aug 10;187:118-32. doi: 10.1016/j.jconrel.2014.05.035. Epub 2014 May 27. Review.

28.

Historical contingency and the gradual evolution of metabolic properties in central carbon and genome-scale metabolisms.

Barve A, Hosseini SR, Martin OC, Wagner A.

BMC Syst Biol. 2014 Apr 23;8:48. doi: 10.1186/1752-0509-8-48.

29.

Fast, electrically controlled polarization modulation of multimode vertical-cavity surface-emitting lasers by RF frequency modulation.

Barve AV, Zheng Y, Johansson LA, Mehta A, Husain A, Coldren LA.

Opt Express. 2013 Dec 16;21(25):31092-7. doi: 10.1364/OE.21.031092.

PMID:
24514683
30.

A photochemical method for determining plasma homocysteine with limited sample processing.

Hakuna L, Escobedo JO, Lowry M, Barve A, McCallum N, Strongin RM.

Chem Commun (Camb). 2014 Mar 21;50(23):3071-3. doi: 10.1039/c4cc00432a.

31.

Structural and sequence similarities of hydra xeroderma pigmentosum A protein to human homolog suggest early evolution and conservation.

Barve A, Ghaskadbi S, Ghaskadbi S.

Biomed Res Int. 2013;2013:854745. doi: 10.1155/2013/854745. Epub 2013 Sep 5.

32.

A novel rapamycin-polymer conjugate based on a new poly(ethylene glycol) multiblock copolymer.

Tai W, Chen Z, Barve A, Peng Z, Cheng K.

Pharm Res. 2014 Mar;31(3):706-19. doi: 10.1007/s11095-013-1192-3. Epub 2013 Sep 26.

33.

A latent capacity for evolutionary innovation through exaptation in metabolic systems.

Barve A, Wagner A.

Nature. 2013 Aug 8;500(7461):203-6. doi: 10.1038/nature12301. Epub 2013 Jul 14.

PMID:
23851393
34.

Conservation of the nucleotide excision repair pathway: characterization of hydra Xeroderma Pigmentosum group F homolog.

Barve A, Ghaskadbi S, Ghaskadbi S.

PLoS One. 2013;8(4):e61062. doi: 10.1371/journal.pone.0061062. Epub 2013 Apr 8.

35.

Growth temperature and genome size in bacteria are negatively correlated, suggesting genomic streamlining during thermal adaptation.

Sabath N, Ferrada E, Barve A, Wagner A.

Genome Biol Evol. 2013;5(5):966-77. doi: 10.1093/gbe/evt050.

36.

Analysis of subwavelength metal hole array structure for the enhancement of back-illuminated quantum dot infrared photodetectors.

Ku Z, Jang WY, Zhou J, Kim JO, Barve AV, Silva S, Krishna S, Brueck SR, Nelson R, Urbas A, Kang S, Lee SJ.

Opt Express. 2013 Feb 25;21(4):4709-16. doi: 10.1364/OE.21.004709.

PMID:
23482003
37.

A fast response highly selective probe for the detection of glutathione in human blood plasma.

Guo Y, Yang X, Hakuna L, Barve A, Escobedo JO, Lowry M, Strongin RM.

Sensors (Basel). 2012;12(5):5940-50. doi: 10.3390/s120505940. Epub 2012 May 8.

38.

Superessential reactions in metabolic networks.

Barve A, Rodrigues JF, Wagner A.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):E1121-30. doi: 10.1073/pnas.1113065109. Epub 2012 Apr 16.

39.

Zinc and liver disease.

Mohammad MK, Zhou Z, Cave M, Barve A, McClain CJ.

Nutr Clin Pract. 2012 Feb;27(1):8-20. doi: 10.1177/0884533611433534. Review. Erratum in: Nutr Clin Pract. 2012 Apr;27(2):305. Mohommad, Mohammad K [corrected to Mohammad, Mohammad K].

40.

A monolithically integrated plasmonic infrared quantum dot camera.

Lee SJ, Ku Z, Barve A, Montoya J, Jang WY, Brueck SR, Sundaram M, Reisinger A, Krishna S, Noh SK.

Nat Commun. 2011;2:286. doi: 10.1038/ncomms1283.

PMID:
21505442
41.

Alcoholic liver disease and malnutrition.

McClain CJ, Barve SS, Barve A, Marsano L.

Alcohol Clin Exp Res. 2011 May;35(5):815-20. doi: 10.1111/j.1530-0277.2010.01405.x. Epub 2011 Feb 1. Review.

42.

Regulation of Nrf2- and AP-1-mediated gene expression by epigallocatechin-3-gallate and sulforaphane in prostate of Nrf2-knockout or C57BL/6J mice and PC-3 AP-1 human prostate cancer cells.

Nair S, Barve A, Khor TO, Shen GX, Lin W, Chan JY, Cai L, Kong AN.

Acta Pharmacol Sin. 2010 Sep;31(9):1223-40. doi: 10.1038/aps.2010.147. Epub 2010 Aug 23.

43.

Mixed tocotrienols inhibit prostate carcinogenesis in TRAMP mice.

Barve A, Khor TO, Reuhl K, Reddy B, Newmark H, Kong AN.

Nutr Cancer. 2010;62(6):789-94. doi: 10.1080/01635581003605896.

44.

A kinetic platform for in silico modeling of the metabolic dynamics in Escherichia coli.

Barve A, Gupta A, Solapure SM, Kumar A, Ramachandran V, Seshadri K, Vali S, Datta S.

Adv Appl Bioinform Chem. 2010;3:97-110. doi: 10.2147/AABC.S14368. Epub 2010 Dec 7.

45.

Mixed-ligand copper(II) maltolate complexes: synthesis, characterization, DNA binding and cleavage, and cytotoxicity.

Barve A, Kumbhar A, Bhat M, Joshi B, Butcher R, Sonawane U, Joshi R.

Inorg Chem. 2009 Oct 5;48(19):9120-32. doi: 10.1021/ic9004642.

PMID:
19780613
46.

Metabolism, oral bioavailability and pharmacokinetics of chemopreventive kaempferol in rats.

Barve A, Chen C, Hebbar V, Desiderio J, Saw CL, Kong AN.

Biopharm Drug Dispos. 2009 Oct;30(7):356-65. doi: 10.1002/bdd.677.

47.

Dietary feeding of dibenzoylmethane inhibits prostate cancer in transgenic adenocarcinoma of the mouse prostate model.

Khor TO, Yu S, Barve A, Hao X, Hong JL, Lin W, Foster B, Huang MT, Newmark HL, Kong AN.

Cancer Res. 2009 Sep 1;69(17):7096-102. doi: 10.1158/0008-5472.CAN-09-0597. Epub 2009 Aug 25.

48.
49.

Drug-induced hepatotoxicity or drug-induced liver injury.

Pugh AJ, Barve AJ, Falkner K, Patel M, McClain CJ.

Clin Liver Dis. 2009 May;13(2):277-94. doi: 10.1016/j.cld.2009.02.008.

PMID:
19442919
50.

Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice.

Barve A, Khor TO, Nair S, Reuhl K, Suh N, Reddy B, Newmark H, Kong AN.

Int J Cancer. 2009 Apr 1;124(7):1693-9. doi: 10.1002/ijc.24106.

Supplemental Content

Support Center